|
Oncotelic Therapeutics Inc (OTLC) |
|
Oncotelic Therapeutics Inc
OTLC's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Oncotelic Therapeutics Inc 's sales fell
in the third quarter of 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 10.2 %
Oncotelic Therapeutics Inc faced net loss in contrast to the net income a year ago in third quarter of 2024
• More on OTLC's Growth
|
|
Oncotelic Therapeutics Inc realized a net loss in trailing twelve months.
Oncotelic Therapeutics Inc realized cash reduction of $ -0 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on OTLC's Valuation
|
|
|
|
|
Oncotelic Therapeutics Inc realized net loss in trailing twelve months.
Oncotelic Therapeutics Inc realized cash outflow of $ -0per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Oncotelic Therapeutics Inc Price to Book Ratio is at 2.33 lower than Industry Avg. of 33.79. and higher than S&P 500 Avg. of 0.01
• More on OTLC's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com